Wyeth Submits NDA For Temsirolimus In Kidney Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Torisel would be the only renal cell carcinoma drug on the market to offer a significant survival benefit, Wyeth says.
You may also be interested in...
Torisel Action Date Extended To July 5
FDA will use extension to examine new tumor evaluation information submitted by Wyeth.
Torisel Action Date Extended To July 5
FDA will use extension to examine new tumor evaluation information submitted by Wyeth.
Wyeth R&D President Robert Ruffolo: An Interview With “The Pink Sheet” DAILY
With Wyeth’s NDA for Torisel pending at FDA April 5, exec outlines Wyeth’s early-stage oncology pipeline in an interview with “The Pink Sheet” DAILY.